Key facts
- Vasowatch’s last known valuation is $1.1M (Mar 2023).
- It has raised $1.2M; the latest was Seed Round ($1.0M) in Mar 2026.
- Notable investors include Matter (Consulting Services (B2B)), VentureWell, Vanderbilt University, Unlock Capital (New York), mHUB — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Vasowatch
- ·The full record, as it builds
Funding rounds
No funding rounds for Vasowatch are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vasowatch
Developer of a postpartum hemorrhage biomarker designed to alert clinicians to unknown hemorrhage risk. The company offers a non-invasive wearable device that monitors maternal physiological data and utilizes a proprietary machine learning algorithm to provide continuous risk assessments and timely alerts to clinical care teams, enabling clinicians to enhance birth outcomes, support proactive intervention and save lives.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2021
- Employees
- 6
- Website
- vasowatch.com/
- Ownership
- Privately Held (backing)
Vasowatch doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vasowatch shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vasowatch in its N-PORT filings yet. We sweep new filings monthly.